A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor

Molecular Pharmacology

Volumn 52, Issue 3, 1997, Pages 499-507

  Jiang, Qiaoling ^a   Guo, Danping ^a   Lee, Brian X ^a   Van Rhee, A Michiel ^a   Kim, Yong Chul ^a   Nicholas, Robert A ^b   Schachter, Joel B ^b   Harden, T Kendall ^b   Jacobson, Kenneth A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLTHIOADENOSINE TRIPHOSPHATE; CYCLIC AMP; EPITOPE; INOSITOL PHOSPHATE; NEUROTRANSMITTER; RHODOPSIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; DATA ANALYSIS; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; SMOOTH MUSCLE FIBER;

EID: 0030758832     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.3.499     Document Type: Article

References (34)

1. Fredholm, B. B., M. P. Abbracchio, G. Burnstock, J. W. Daly, T. K. Harden, K. A. Jacobson, P. Leff, and M. Williams. Nomenclature and classification of purinoceptors: a report from the IUPHAR subcommittee. Pharmacol. Rev. 46:143-156 (1994).
2. 2Y purinoceptors? Pharmacol. Ther. 64:445-475 (1994).
3. Burnstock, G., and B. F. King. Numbering of cloned P2 purinoceptors. Drug Dev. Res. 38:67-71 (1996).
4. van Rhee, A. M., and K. A. Jacobson. Molecular architecture of G protein-coupled receptors. Drug Dev. Res. 37:1-38 (1996).
5. 2a adenosine receptor. J. Biol. Chem. 270:13987-13997 (1995).
6. 2A adenosine receptors are required for ligand recognition. Mol. Pharmacol 50:512-521 (1996).
7. 1 adenosine receptor: studies on the ligand binding site by site-directed mutagenesis. J. Biol. Chem. 267:10764-10770 (1992).
8. 1-adenosine receptor mediates specific agonist binding. J. Biol. Chem. 269:2373-2376 (1994).
9. 1 adenosine receptors: 2 amino-acids are responsible for species-differences in ligand recognition. J. Biol. Chem. 269: 27900-27906 (1994).
10. 2a adenosine receptors. J. Biol. Chem. 270:20485-20490 (1995).
11. 2U purinoceptors: positively charged amino-acids in transmembrane helix-6 and helix-7 affect agonist potency and specificity. J. Biol. Chem. 270:4185-4188 (1995).
12. 2Y purinoceptor using rhodopsin as template. Drug Design Discovery 13:133-154 (1995).
13. van Rhee, A. M., L. Erb, R. Garrad, and K. A. Jacobson. P2 receptor modeling and identification of ligand binding sites, in The Receptors: The P2 Nucleotide Receptors (J. T. Turner, G. Weisman, and J. Fedan, eds.). Humana Press, Clifton, NJ (1997).
14. Ballesteros, J. A., and H. Weinstein. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci. 25: 366-428 (1995).
15. Schertler, G. F., C. Villa, and R. Henderson. Projection structure of rhodopsin. Nature (Lond.) 362:770-772 (1993).
16. Baldwin, J. M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 12:1693-1703 (1993).
17. Hibert, M. F., S. Trumpp-Kallmeyer, A. Bruinvels, and J. Hoflack. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol. Pharmacol. 40:8-15 (1991).
18. 2Y-purinoceptor agonists: structure activity relationships for 2-thioether derivatives of adenosine-5′-triphosphate. J. Med. Chem. 36:3937-3946 (1993).
19. 2Y-subtypes. Drug Dev. Res. 31:206-219 (1994).
20. 2Y purinoceptor agonists that are derivatives of adenosine 5′-monophosphate. Br. J. Pharmacol. 118:1959-1964 (1996).
21. 1-purinoceptor. Br. J. Pharmacol. 118:167-173 (1996).
22. Okayama, H., and P. A. Berg. A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells. Mol. Cell. Biol. 3:280-289 (1983).
23. Higuchi, R. Using PCR to engineer DNA, in PCR Technology (H. A. Ehrlich, ed.). Stockton Press, New York, 61-70 (1989).
24. Sanger, R., S. Nicklen, and A. R. Coulson. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467 (1977).
25. 2a-adenosine receptors with hexahistidine and the flag epitope: development of an efficient generic protein-purification procedure. Biochem. Pharmacol. 51:545-555 (1996).
26. Cullen, B. R. Use of eukaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol 152:684-704 (1987).
27. Harden, T. K., P. T. Hawkins, L. Stephens, J. L. Boyer, and P. Downes. Phosphoinositide hydrolysis by guanosine 5′-(γ-thio)triphosphate-activated phospholipase C of turkey erythrocyte membranes. Biochem. J. 252:583-593 (1988).
28. Berridge, M. J., R. M. Dawson, C. P. Downes, J. P. Heslop, and R. F. Irvine. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J. 212:473-482 (1983).
29. 2Y purinergic receptors. Br. J. Pharmacol. 113: 614-620 (1994).
30. Simon, J., T. E. Webb, B. F. King, G. Burnstock, and E. A. Barnard. Characterization of a recombinant P2Y purinoceptor. Eur. J. Pharmacol. 291:281-289 (1995).
31. 1 receptor. Br. J. Pharmacol. 121:338-344 (1997).
32. 35S]ADPβS binding to bovine brain membranes. Pharmacol. Commun. 1:279-290 (1992).
33. Strader, C. D., M. R. Candelore, W. S. Hill, I. S. Sigal, and R. A. F. Dixon. Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J. Biol. Chem. 264:13572-13578 (1989).
34. 2 receptor by the substituted-cysteine accessibility method. Neuron 14:825-31 (1995).